Daily non-political popular news in brief.

Evidence found for genes that affect risk of developing Alzheimer's disease

01-17-2008 · EurekAlert!

Through one of the largest studies yet of Alzheimer's disease patients and their brothers, sisters, and children, researchers at Mayo Clinic Jacksonville have found strong evidence that genes other than the well-known susceptibility risk factor APOE4 influence who is at risk for developing the neurodegenerative disease later in life.

Keywords: evidence, genes, affect, risk, developing, alzheimer, disease, gene

« Previous | Next »

Similar news on "Evidence found for genes that affect risk of developing Alzheimer's disease":

Research team identifies new Alzheimer's gene
06-06-2007 · EurekAlert!
A study comparing more genetic markers in the DNA of people with and without Alzheimer's disease than ever before enabled researchers to identify a common gene that appears to increase one's risk for developing Alzheimer's disease. The finding by researchers at the Translational Genomics Research Institute, Banner Alzheimer's Institute, Kronos Science Laboratory and their collaborative partners, suggests that the gene -- called GAB2 -- modifies an individual's risk when associated with other genes, including APOE4.
Similar news · Read more »
'Diabetes gene' may be linked to polycystic ovary syndrome
12-06-2006 · EurekAlert!
A study of polycystic ovary syndrome (PCOS) provides further evidence that calpain-10, the "diabetes gene," is related to PCOS susceptibility. PCOS affects up to five percent of the female population, and those diagnosed with the disease have a 2- to 7-fold risk of developing type 2 diabetes mellitus. The data suggest that one area of the gene, the SNP ins/del-19, may be related to both PCOS and type 2 diabetes.
Similar news · Read more »
Drug that lowers blood pressure might help prevent Alzheimer's disease
10-25-2007 · EurekAlert!
Alzheimer's disease is a neurodegenerative disease that is the most common form of dementia. Recent evidence indicates that some drugs used to treat high blood pressure might reduce the risk of developing AD. In a new study, the antihypertensive medication valsartan has been shown to reduce AD-like disease in mice.
Similar news · Read more »
Women testing negative for familial breast cancer gene still at increased risk
10-30-2006 · EurekAlert!
Women testing negative for the two inherited breast cancer genes are still at increased risk of developing the disease, suggests research published ahead of print in the Journal of Medical Genetics.
Similar news · Read more »
Children with gene show reduced cognitive function
11-05-2007 · EurekAlert!
Children possessing a gene known to increase Alzheimer's disease risk already show signs of reduced cognitive function, an Oregon Health & Science University study has found. Scientists discovered that 7- to 10-year-olds with a member of a family of genes implicated in development, nerve cell regeneration and neuroprotection display reduced spatial learning and memory, associated with later-life cognitive impairments. This suggests brain changes predisposing a person to Alzheimer's might occur much sooner than previously thought.
Similar news · Read more »
New study zeroes in on genetic roots of Alzheimer's
04-10-2007 · EurekAlert!
Scientists have long known that individuals with a certain gene are at higher risk for developing Alzheimer's disease. Now a new study helps explain why this is so. The research, led by scientists at the Oklahoma Medical Research Foundation, has uncovered a molecular mechanism that links the susceptibility gene to the process of Alzheimer's disease onset. The findings appear in the Journal of Neuroscience and may lead to new pathways for development of Alzheimer's therapeutics.
Similar news · Read more »
Advance in understanding of blood pressure gene could lead to new treatments
02-04-2007 · EurekAlert!
Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
Similar news · Read more »
New Alzheimer's findings: High stress and genetic risk factor lead to increased memory decline
08-27-2007 · EurekAlert!
High stress levels may contribute to memory loss among people at risk for developing Alzheimer's disease. The å4 variant of the apolipoprotein E (APOE) gene contributes to the risk for memory loss related to Alzheimer's disease.
Similar news · Read more »
Engineered mice provide insight into Alzheimer's disease
01-17-2008 · EurekAlert!
One factor that determines an individual's risk of developing Alzheimer's disease is the version of the APOE gene that they carry. It has been hypothesized that increasing the amount of fat associated with apoE by overexpressing ABCA1 might decrease amyloid deposition in the brain, the hallmark of AD. Support for this hypothesis has now been generated in mice, suggesting that increasing the function of ABCA1 in the brain might benefit individuals with AD.
Similar news · Read more »
Study examines genetic risk factors for Alzheimer's disease
03-05-2007 · EurekAlert!
Cardiff University researchers have found evidence for new genes involved in the development of Alzheimer’s disease.
Similar news · Read more »